On December 6, 2025, Ascentage Pharma Group International Inc. disclosed at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, FL, that their Phase II study in China involving Lisaftoclax (APG-2575) for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma patients who failed Bruton’s tyrosine kinase inhibitors (BTKis) was successful. The National Medical Products Administration (NMPA) of China approved Lisaftoclax in July 2025 following data from this critical trial. Ascentage Pharma Group, a biopharmaceutical company traded on NASDAQ (AAPG) and HKEX (6855), specializes in developing innovative therapies for cancer treatment.